China-based Kexing Pharmaceutical (SHA: 688136) has entered into an overseas cooperation agreement with fellow domestic firm Yabao Pharmaceutical Group Co., Ltd. (SHA: 600351) to distribute a generic version of Bayer (ETR: BAYN)’s Nexavar (sorafenib). Under this agreement, Kexing will serve as the exclusive agent for the tyrosine kinase inhibitor (TKI) across an initial group of ten countries, including Peru, Singapore, and Malaysia.
Sorafenib functions as an inhibitor of various intracellular and cell surface kinases, including c-CRAF, BRAF, and VEGFRs, and is approved for treating advanced renal cell carcinoma, hepatocellular carcinoma, FLT3-ITD positive acute myeloid leukemia, and radiation iodine-resistant advanced thyroid cancer. Yabao’s generic version received regulatory approval in China in 2021 and in the United States in 2022.- Flcube.com
